ChronoScale Corporation Common Stock (NASDAQ:CHRN – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.
Profitability
This table compares ChronoScale Corporation Common Stock and Delcath Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ChronoScale Corporation Common Stock | -135.66% | -197.81% | -74.17% |
| Delcath Systems | 0.62% | 0.51% | 0.46% |
Valuation and Earnings
This table compares ChronoScale Corporation Common Stock and Delcath Systems”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ChronoScale Corporation Common Stock | $84.38 million | 0.70 | -$11.69 million | ($5.38) | -3.09 |
| Delcath Systems | $85.23 million | 4.70 | $2.70 million | $0.01 | 1,161.00 |
Delcath Systems has higher revenue and earnings than ChronoScale Corporation Common Stock. ChronoScale Corporation Common Stock is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
ChronoScale Corporation Common Stock has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Institutional & Insider Ownership
6.4% of ChronoScale Corporation Common Stock shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 6.9% of ChronoScale Corporation Common Stock shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for ChronoScale Corporation Common Stock and Delcath Systems, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ChronoScale Corporation Common Stock | 1 | 1 | 0 | 0 | 1.50 |
| Delcath Systems | 2 | 0 | 5 | 0 | 2.43 |
ChronoScale Corporation Common Stock presently has a consensus price target of $6.00, suggesting a potential downside of 63.92%. Delcath Systems has a consensus price target of $22.50, suggesting a potential upside of 93.80%. Given Delcath Systems’ stronger consensus rating and higher possible upside, analysts plainly believe Delcath Systems is more favorable than ChronoScale Corporation Common Stock.
Summary
Delcath Systems beats ChronoScale Corporation Common Stock on 13 of the 14 factors compared between the two stocks.
About ChronoScale Corporation Common Stock
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Receive News & Ratings for ChronoScale Corporation Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChronoScale Corporation Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
